抑制剂 拮抗剂 激动剂 化合物库 天然产物 中间体 药物杂质

Product Name:

Sunitinib Malate CAS No.:

341031-54-7

Product Data Sheet

Cat. No.:

HY-10255MWt:

532.56Formula:

C26H33FN4O7Purity :

>98%

Solubility:Mechanisms:

Biological Activity:

Pathways:Protein Tyrosine Kinase/RTK; Target:VEGFR DMSO ≥102mg/mL Water ≥6.6mg/mL Ethanol <1.2mg/mL

g y Sunitinib is potent, ATP-competitive VEGFR, PDGFR β and KIT inhibitor (Ki values are 2, 9, 17, 8and 4 nM for VEGFR -1, -2, -3, PDGFR β and KIT respectively). Sunitinib also inhibits cellular

receptor phosphorylation of FLT3, RET and CSF-1R. Sunitinib exhibits antiangiogenic and antitumor activity in multiple xenograft models

References:

[1]. Faivre et al (2007) Molecular basis for sunitinib efficacy and future clinical development.

Nat.Rev.Drug

Discov. 6 734.[2]. Roskoski (2007) Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis []()p p g g

inhibitor.

m. 356 323.[3]. Penot P, Bouaziz JD, Battistella M, Kerob D, Pagès C, Vilmer C, Basset-Seguin N, Madjessli N,Comte C, Farges C, Bagot M, le Maignan C, Lebbé C.Multiple metastatic epithelioid sarcoma

stabilization under sunitinib malate treatment.Br J Dermatol. 2012 Sep 10.[4]. Nowak AK, Millward MJ, Creaney J, Francis RJ, Dick IM, Hasani A, van der Schaaf A, Segal A,Musk AW, Byrne MJ.A Phase II Study of Intermittent Sunitinib Malate as Second-Line Therapy in

Progressive Malignant Pleural Mesothelioma.J Thorac Oncol. 2012 Sep;7(9):1449-56.[5]C SM P RT M t l i U H it NS Wh l C P Caution: Not fully tested. For research purposes only

Medchemexpress LLC

[5]. Campos SM, Penson RT, Matulonis U, Horowitz NS, Whalen C, Pere...

18 W i l k i n s o n W a y , P r i n c e t o n , N J 08540,U S A

E m a i l : i n f o @m e d c h e m e x p r e s s .c o m W e b : w w w .m e d c h e m e x p r e s s .c o

m